Adverse Event Management

A study of patients with chronic lymphocytic leukemia looked into the role of treatment and disease itself in cognitive impairment.

Opioids are the go-to treatment for cancer-related pain. But is this mainstay poised to change as the opioid crisis continues to grow?

Malnutrition is a potentially fatal adverse event that many patients undergoing treatment for cancer will face, but it's an adverse event that can be dealt with ahead of time during the first visit with an oncology nurse.

CAR T-cell therapies are a revolutionary form of treatment for patients with cancer, but it does come with its unique adverse events.

While immunotherapy can be a life-saving approach for many patients with cancer, there are some cardiac adverse events that nurses should look out for.

An expert discusses 2 new surgical treatments for breast cancer-associated lymphedema.

With the approval of 2 new JAK inhibitors for the management and treatment of myelofibrosis, the space is undergoing a new progression, with lots of questions left to answer.

About a third of breast cancer survivors are still living with fatigue and reduced exercise capacity after treatment ends.

When patients are experiencing cancer-related fatigue, oncology nurses might want to consider referring them to cognitive behavior therapy (CBT).

Financial toxicity can have an impact on patients' anxiety and depression, but oncology nurses can help.

One expert discusses how immunotherapy is changing the treatment – and adverse event – landscape in oncology.

Patients are getting a ton of information from outside sources and advertisements about new immunotherapy agents. It is crucial that providers offer them the key facts that they need.

Like most other adverse events (AEs), nurses play a vital role in monitoring for and managing endocrine toxicities associated with immunotherapy treatment; however, these may be more unique than others, according to Marianne Davies, DNP, RN, CNS, ACNP-BC, AOCNP.

Nurses should know what to look for when it comes to managing dermatologic toxicities.

There are multiple steps nurses must take to prevent and manage pulmonary toxicities in patients taking immunotherapy.

Nurses can lead the healthcare team when it comes to managing immune-related GI toxicities.

To start, nurses must be able to prevent and anticipate GI toxicities.

Patients experiencing chemotherapy-induced nausea and vomiting (CINV) need to understand what can be done to help their symptoms, and oncology nurses can educate them on what is best to take for CINV.

Hair, skin, or nail reactions commonly occur in patients treated with immunotherapy and targeted therapy for cancer.

At the 3rd annual School of Nursing Oncology (SONO) meeting, we got the chance to sit down with Madelaine Kuiper RN, MSN, and talk about what adverse events come with immune therapy for patients with breast cancer.

To assist in treating patients with immune-related adverse events (irAEs), nurses can follow 5 pillars: prevent, anticipate, detect, treat, and monitor.

It is crucial for nurses to be aware of adverse events that can occur in patients who are receiving CAR T-cell therapy, explained one expert.

Many adolescent and young adult cancer survivors struggle in the post-cancer period. Oncology nurses can help ensure that they don’t fall through the cracks.

A new surgical method could help treat lymphedema, according to one expert.

Light therapy can be used to prevent oral mucositis in patients with cancer, according to one expert.

Symptom management and proper risk stratification are two crucial ways to improve the care of patients with myeloproliferative neoplasms, according to one expert.

An expert discusses the cardiac toxicity of ABP 980, a trastuzumab biosimilar, in the breast cancer space.

Cancer-related cognitive impairments affect many survivors of the disease, and can have major impacts on their daily living.

With more people surviving long after their cancer diagnosis, there is also a heightened risk of developing chronic health conditions.

Oncology nurses shouldn’t be concerned if patients with non-small cell lung cancer experience skin toxic effects after immunotherapy.